Xe/CT Cerebral Blood Flow Evaluation of Delayed Symptomatic Cerebral Ischemia after Subarachnoid Hemorrhage

Melanie B. Fukui,1 David W. Johnson,1 Howard Yonas,2 Laligam Sekhar,2 Richard E. Latchaw,3 and Susan Pentheny1

Purpose: We examined the xenon/CT method of measuring cerebral blood flow in assessing the location, pattern of onset, and severity of delayed cerebral ischemia. Patients and Methods: Fourteen patients with delayed neurologic deficits due to ischemia were selected from a group of 66 patients with subarachnoid hemorrhage. All blood flow studies were performed within 12 hours of deterioration and at regular intervals during medical management. Results: In 10 of the 14 patients, noncontrast CT did not identify a cause for deterioration, whereas the blood flow study revealed diminished flow values. Location of blood flow reduction was variable. In five of the 14 patients, blood flow reduction was closely related anatomically to the vessel of aneurysm origin. In another three, blood flow reduction was anatomically remote to the vessel of origin. The remaining six experienced local and remote cerebral blood flow reduction. Six of 14 patients suffered sudden, devastating deterioration, refractory to therapy and associated with blood flow of 15 cc/100 g·min or less, resulting in local or widespread infarction. The remaining eight had less severe blood flow reduction and did not infarct those territories. Conclusions: Vasospasm can affect remote vessels as severely as local vessels and can affect remote vessels alone. Diminished cerebral blood flow correlated closely with clinical vasospasm in this group of patients. Xenon/CT cerebral blood flow studies can identify tissue at risk of infarction when CT is normal.

Index terms: Cerebral blood flow; Computed tomography, xenon study; Brain, ischemia; Aneurysm, cerebral


Delayed cerebral ischemia due to vasospasm is one of the most devastating sequelae of subarachnoid hemorrhage (SAH) secondary to ruptured aneurysms. Usually, diagnosis of symptomatic vasospasm following SAH has been made by patient history and physical exam with computed tomography (CT) and/or angiographic confirmation. The findings of headache, fever, elevated white blood cell count, and delayed neurologic deficit are helpful, but not specific, for vasospasm.

Although angiography is considered to be the standard for diagnosing vasospasm, it is associated with a high rate of morbidity after SAH (1). Many authors have suggested the use of noninvasive cerebral blood flow (CBF) studies to measure tissue perfusion as an alternative to angiography in the diagnosis and management of vasospasm (2-4). In fact, noninvasive CBF studies have proved useful in identifying patients with initially reduced CBF values, who, despite good clinical grade, are at risk for developing vasospasm (4, 5).

We have used the xenon/CT (Xe/CT) CBF method because of its accessibility, capacity for direct anatomic correlation, and sensitivity in detecting CBF values near zero. Xe/CT CBF studies have provided useful information in the evaluation of delayed cerebral ischemia by identifying tissue at risk for infarction.

Methods

Fourteen patients with delayed neurologic deficits were selected from a group of 66 patients with SAH due to...
aneurysm rupture. The 52 remaining patients were asymptomatic and had normal Xe/CT CBF studies. No electrolyte imbalance, evidence of hydrocephalus, or rebleeding was detected coincident with the onset of neurologic deficit. Patients were graded according to the Hunt and Hess classification (6). Xe/CT CBF studies, along with CT imaging, were performed on all 14 patients within 12 hours of delayed neurologic deficit. Those treated with medical therapy were also scanned 4-6 days and 8–10 days after SAH.

Xe/CT CBF studies were performed on a GE 9800 CT scanner equipped with an integrated hardware and software system for measurement and calculation of CBF (GE Medical Systems, Milwaukee, WI). Patients were connected to a gas delivery system that supplies a 33% xenon/67% oxygen mixture. Two baseline scans were obtained at each level of study before xenon delivery. Four to six enhanced images were obtained during the first 4.5 minutes of xenon inhalation. A more detailed description of the method has previously been reported (7). CBF data were quantified by placing multiple 2-cm diameter or greater regions of interest over the cerebral cortex.

**Results**

The onset of symptoms of delayed ischemia due to vasospasm was typical, and ranged from 3–10 days post hemorrhage (Table 1). In 10 of 14 patients with delayed neurologic deficits, CT did not identify a cause for deterioration; however, CBF studies revealed diminished flow values that corresponded to the clinical deficits. In the remaining four patients, CT revealed infarcts, and the concurrent CBF studies showed significantly larger areas of compromised blood flow.

The distribution of ischemia varied. In five patients, reduction of CBF was anatomically closely related to the vessel of origin, which we termed local. In three patients, the reduction of CBF was anatomically unrelated to the vessel of origin, which we termed remote. The CBF studies of six patients demonstrated both local and remote reductions in CBF. The distribution of aneurysm origin is listed in Table 1. There was no clear difference in outcome based on the distribution of cerebral ischemia.

Six patients suffered sudden, devastating neurologic deterioration that was refractory to hypertensive therapy. Initial CBF values after the onset of symptoms of less than 15 cc/100 g·min, often near zero, were measured in these patients and were accompanied by local or global infarction on CT. The remaining eight patients had less severe reductions in CBF and responded to therapy with increased CBF and no CT-defined infarction.

**Cases**

**Patient 4: Local Vasospasm**

A 24-year-old man presented five days after the initial SAH and 1 day after rebleeding from a ruptured anterior communicating artery aneurysm. The initial CT showed a minimal amount of blood in the cistern of the lamina terminalis and the frontal interhemispheric cistern. Twenty-four hours after operation for aneurysm clipping, the patient rapidly developed left-sided weakness,
leg greater than arm. A CBF study showed decreased flow values in both anterior cerebral artery (ACA) territories: 5 cc/100 g·min on the right and 20 cc/100 g·min on the left (Figs. 1A and 1B). With pressors and volume expansion, the patient's neurologic course stabilized. A repeat CBF study showed improved blood flow (30 cc/100 g·min) in the left ACA territory, and persistence of flow values near zero on the right, corresponding to a right ACA infarct on CT (Figs. 1C and 1D).

**Patient 9: Local and Remote Vasospasm**

A 46-year-old man was grade 1 on transfer to our hospital, three days after SAH from a ruptured ACA aneurysm. CT performed on day 1 showed a large amount of subarachnoid blood at the base of the brain and over the convexities; this had resolved by the first CBF study performed on day 3. The study showed diminished blood flow values in the arterial border zones, and near normal flows in the sylvian regions of the brain (Figs. 2A and 2B).

The following day, the patient suddenly became comatose. Although CT did not show infarct or new hemorrhage, a second CBF study showed severely decreased flow values (less than 15 cc/100 g·min) in the ACA and middle cerebral artery (MCA) territories bilaterally (Figs. 2C and 2D). The patient died within 24 hours.

**Patient 6: Remote Vasospasm**

A 40-year-old woman was transferred to our hospital five days after SAH from a ruptured basilar tip aneurysm. She presented with frontal lobe dysfunction and severe hypertension (blood pressure, 190/120). CT showed a minimal amount of blood in the ventricles and the interpeduncular fossa. The initial CBF study showed diminished flow values in the frontal lobes (20 cc/100 g·min) (Fig. 3A). Normal flows were noted in the thalamus, basal ganglia, and calcarine cortex.

Five days later, she became oriented and her blood pressure returned to normal spontaneously. A second CBF study revealed markedly elevated flow values diffusely (greater than 70 cc/100 g·min), including the previously ischemic frontal lobes (Fig. 3B). Within hours of the onset of hyperemic flows, the patient rebled and died.

**Discussion**

When hyponatremia, hydrocephalus, and rebleeding have been excluded as causes for delayed neurologic deterioration after SAH, ischemia due to vasospasm is implicated (8). The demonstration by angiography of narrowed blood vessels has been the standard for diagnosing vasospasm, but it is not a good predictor of clinical outcome. Although vasospasm is seen on approximately 30%–40% of arteriograms 4–12

---

**Fig. 1.** Patient 4: local vasospasm; anterior communicating artery aneurysm.

A, Six days post SAH Xe/CT CBF study shows decreased blood flow in both ACA territories: 5 cc/100 g·min on the right (solid arrows) and 20 cc/100 g·min on the left (open arrows).

B, The accompanying CT scan shows normal brain parenchyma.

C, Three days later (9 days post SAH), and after hypertension and hemodilution therapy, a repeat CBF study shows improved blood flow in the left ACA territory (30 cc/100 g·min) (open arrows) and persistent low blood flow (5 cc/100 g·min) on the right (solid arrows).

D, CT shows the corresponding infarct in the right ACA territory.
days after SAH (9-12), only 20%-30% of patients experience delayed neurologic deterioration (13-16). Schneck and Kricheff reported a poor correlation between angiographic vasospasm and cerebral infarction after SAH (17). Angiographic vasospasm does not reliably predict clinically significant ischemia. Other investigators have reported that angiographic arterial narrowing is limited to the major vascular territory corresponding to the aneurysm origin (3, 13). These observations may be explained by the fact that angiography demonstrates the major basal and cortical arteries only, and cannot detect small vessel narrowing. Since there must be at least 80% narrowing of the vessel lumen (18) before the distal circulation is affected, focal ischemia and infarcts do not consistently follow angiographic vasospasm (19). Global reductions in CBF measured with Xe133 correlated poorly with the distribution of arterial narrowing by angiography (20); this is further evidence of the limited scope of angiography in the evaluation of ischemia. The discrepancy between angiographic findings and clinical signs of ischemia, coupled with a report of the high degree of variability in the interpretation of angiographic vasospasm (21), suggests that angiography is unreliable and not the best technique for the diagnosis of clinically significant vasospasm. Although the cause of vasospasm is not well understood, the risk of secondary ischemia leading to infarction is undisputed.

The Xe/CT technique for measuring CBF provides a noninvasive method to evaluate ischemia. Some investigators have reported poor correlation between diminished CBF and neurologic deficits (19), while others have measured diminished CBF in clinically affected territories (22, 23). In our group of patients, CBF of 20 cc/100 g·min or less correlated closely with neurologic deficits. These results confirm those that Powers et al obtained using positron emission tomography (PET) (24). Although CT alone has been used to correlate acute focal hemorrhage with vasospasm
(13), delayed ischemia may occur in the absence of CT-defined hemorrhage. In 10 of 14 cases in our series with delayed neurologic deficits and dramatic reduction of CBF, CT scans were normal at the time of symptoms. We found Xe/CT was more sensitive than CT alone in detecting foci of ischemia that corresponded to neurologic deficits.

Despite the advantages of Xe/CT in the evaluation of symptomatic vasospasm, there are limitations. The disadvantages of radiation dose and pharmacologic effects of xenon have been discussed previously (7) and are considered to be acceptable in the risk benefit analysis. The most important pharmacologic effects of xenon, including respiratory depression and bronchospasm, have occasionally resulted in termination of the study, but no deaths have been reported. Giller et al reported alteration in cerebral blood velocity associated with xenon inhalation (25). They believed this could impair the ability of the Xe/CT technique to measure CBF reliably. Although a rise in cerebral blood velocity could compromise the accuracy of Xe/CT CBF measurement, other studies have indicated that because this activation of CBF occurs only after 2 minutes, it has an insignificant impact on the calculated CBF (26, 27).

The work of Fisher et al showing the proximity of vasospasm to retained subarachnoid hematoma by CT (13) reflects the current thinking that clinical vasospasm is most severe at the vessel of aneurysm origin and is proportional to the extent of SAH. In our series, delayed cerebral ischemia was variable in distribution. In 11 of 14 patients, reduction of CBF occurred in the territory of the vessel of aneurysm origin, although six of these 11 patients had additional areas of reduced CBF remote from the vessel of origin. Three patients experienced remote ischemia exclusively. This challenges the concept that vasospasm is related to or caused by focal hematoma. The observation that delayed cerebral ischemia can occur remote from the vessel of aneurysm origin suggests that CT alone is not an adequate predictor of location/severity of vasospasm.

Delayed ischemia typically is gradual in onset and responsive to hypervolemic therapy; however, we observed a high degree of variability in the time course and severity of CBF reduction. Eight patients experienced gradual reduction in CBF (20–25 cc/100 g·min), with mild to moderate neurologic impairment that responded to therapy without CT-defined infarction. These results are similar to those of Symon (28). Six patients, however, suffered sudden, devastating deterioration with an abrupt reduction in CBF to 15 cc/100 g·min or less, resulting in local or global infarction that was unresponsive to therapy. In addition to a correlation between symptoms and low CBF, a positive correlation between CBF of 15 cc/100 g·min or less and infarction has also been observed by Powers et al using PET (24). The rapid onset of severe vasospasm refractory to medical therapy, however, has been described as very unusual (29). Although the high frequency with which rapid deterioration was observed in our series may be due, in part, to the small patient population, the important benefit of CBF measurement is the potential to identify patients who may not improve with therapy.

Some have suggested that delayed cerebral ischemia after SAH might be due to diminished metabolism (18) or small vessel spasm undetected by angiography (5). Knuckey et al stated that narrowing of high-resistance arterioles might explain diminished CBF that is not attributable to large vessel narrowing (5). The possible roles of arteriolar narrowing and altered metabolism might account for the distribution and severity of ischemia in our series. Although it would be ideal to obtain data on CBF and cerebral metabolism on aneurysm patients, PET data suggest that local CBF alone can predict irreversible ischemia in patients with vasospasm (24).

Our results confirm the complexity of delayed cerebral ischemia and suggest that alternate theories must be invoked to explain cases of remote ischemia. Current theories for the pathogenesis of vasospasm include chemical factors, such as prostaglandins (30, 31), catecholamines (32, 33), serotonin (31, 32, 34), and angiotensin (35); mechanical factors, such as stretching of arachnoid fibers, “chordae” (36); and morphologic changes in vessels, such as myonecrosis (37). None of these theories, with the exception of the mechanical theory of Arutiuonov et al (36), precludes the possibility of ischemia occurring remote from the vessel of origin.

Medical treatment for vasospasm includes hemo dilution and hypertensive therapy to improve blood rheology and remains the initial treatment for vasospasm. With recent advances in the use of angioplasty in the treatment of vasospasm, Xe/CT may prove to be a useful tool in making management decisions. Early reports of the use of angioplasty in the treatment of vasospasm suggest high success rates ranging from 71% to 75% (38, 39).
Clinical vasospasm is a poorly understood disease. Our series demonstrates that both the vessel of origin and remote vessels can be equally and severely affected. One or more vascular territories can be devastated early and rapidly progress to infarction despite aggressive medical therapy. Local and remote vascular territories may be less severely affected, revealing a marginal CBF above the minimum (15 cc/100 g-min) for tissue viability, but not precluding a normal CT scan.

References


AJNR: 13, January/February 1992